» Articles » PMID: 35154073

The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer

Overview
Journal Front Immunol
Date 2022 Feb 14
PMID 35154073
Authors
Affiliations
Soon will be listed here.
Abstract

Buruli ulcer (BU), caused by , is a devastating necrotizing skin disease. Key to its pathogenesis is mycolactone, the exotoxin virulence factor that is both immunosuppressive and cytotoxic. The discovery that the essential Sec61 translocon is the major cellular target of mycolactone explains much of the disease pathology, including the immune blockade. Sec61 inhibition leads to a loss in production of nearly all cytokines from monocytes, macrophages, dendritic cells and T cells, as well as antigen presentation pathway proteins and costimulatory molecules. However, there has long been evidence that the immune system is not completely incapable of responding to infection. In particular, IL-1β was recently shown to be present in BU lesions, and to be induced from -exposed macrophages in a mycolactone-dependent manner. This has important implications for our understanding of BU, showing that mycolactone can act as the "second signal" for IL-1β production without inhibiting the pathways of unconventional secretion it uses for cellular release. In this Perspective article, we validate and discuss this recent advance, which is entirely in-line with our understanding of mycolactone's inhibition of the Sec61 translocon. However, we also show that the IL-1 receptor, which uses the conventional secretory pathway, is sensitive to mycolactone blockade at Sec61. Hence, a more complete understanding of the mechanisms regulating IL-1β function in skin tissue, including the transient intra-macrophage stage of infection, is urgently needed to uncover the double-edged sword of IL-1β in BU pathogenesis, treatment and wound healing.

Citing Articles

The toxin mycolactone causes destructive Sec61-dependent loss of the endothelial glycocalyx and vessel basement membrane to drive skin necrosis.

Hsieh L, Hall B, Newcombe J, Mendum T, Varela S, Umrania Y Elife. 2025; 12.

PMID: 39913180 PMC: 11801798. DOI: 10.7554/eLife.86931.


Computational and GC-MS screening of bioactive compounds from Thymus Vulgaris targeting mycolactone protein associated with Buruli ulcer.

Naveed M, Ali I, Aziz T, Saleem A, Rajpoot Z, Khaleel S Sci Rep. 2025; 15(1):131.

PMID: 39747211 PMC: 11696270. DOI: 10.1038/s41598-024-83908-0.


Inflammasome-triggered IL-18 controls skin inflammation in the progression of Buruli ulcer.

Suzuki T, Boonyaleka K, Okano T, Iida T, Yoshida M, Fukano H PLoS Pathog. 2023; 19(11):e1011747.

PMID: 37910490 PMC: 10619818. DOI: 10.1371/journal.ppat.1011747.


Type-I interferons promote innate immune tolerance in macrophages exposed to Mycobacterium ulcerans vesicles.

Bernard Q, Goumeidane M, Chaumond E, Robbe-Saule M, Boucaud Y, Esnault L PLoS Pathog. 2023; 19(7):e1011479.

PMID: 37428812 PMC: 10358927. DOI: 10.1371/journal.ppat.1011479.


Changes in Inflammatory Markers in Patients Treated for Buruli Ulcer and Their Ability to Predict Paradoxical Reactions.

Phelippeau M, Marion E, Robbe-Saule M, Ganlanon L, Chauty A, Adeye A J Infect Dis. 2023; 228(11):1630-1639.

PMID: 37221015 PMC: 10681857. DOI: 10.1093/infdis/jiad176.


References
1.
Demangel C, High S . Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease. Biol Cell. 2018; 110(11):237-248. DOI: 10.1111/boc.201800030. View

2.
Pahlevan A, Wright D, Andrews C, George K, Small P, Foxwell B . The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol. 1999; 163(7):3928-35. View

3.
Guenin-Mace L, Veyron-Churlet R, Thoulouze M, Romet-Lemonne G, Hong H, Leadlay P . Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013; 123(4):1501-12. PMC: 3613928. DOI: 10.1172/JCI66576. View

4.
Bolz M, Ruggli N, Borel N, Pluschke G, Ruf M . Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model. PLoS Negl Trop Dis. 2016; 10(4):e0004678. PMC: 4851394. DOI: 10.1371/journal.pntd.0004678. View

5.
Gushiken L, Beserra F, Bastos J, Jackson C, Pellizzon C . Cutaneous Wound Healing: An Update from Physiopathology to Current Therapies. Life (Basel). 2021; 11(7). PMC: 8307436. DOI: 10.3390/life11070665. View